ImmunityBio, Inc. (NASDAQ:IBRX), a commercial-stage immunotherapy company, disclosed significant financial and operational progress for 2025 in a newly filed SEC Form 8-K, highlighting sharp revenue growth, expanding product approvals and advancing international partnerships.
Financial Performance
The company reported full-year net product revenue of $113 million for 2025, representing an approximately 700% increase compared with the prior year. Unit sales volume rose 750% over the same period.
Fourth-quarter net product revenue totaled $38.3 million, up 431% year over year from Q4 2024. Despite the strong commercial growth, ImmunityBio posted a net loss attributable to common stockholders of $351.4 million for the year, an improvement from a $413.6 million loss recorded in 2024.
Operational and Commercial Milestones
During 2025, ImmunityBio expanded regulatory approvals for its lead therapy ANKTIVA® in lung and bladder cancer indications across 33 countries. To support commercialization, the company entered strategic partnerships with Accord Healthcare in the European Union and BioPharma & Cigalah in Saudi Arabia.
The company also established new subsidiaries in Dublin and Saudi Arabia, strengthening its operational footprint across Europe and the Middle East and North Africa (MENA) region.
Strategic Development Initiatives
ImmunityBio continues to advance a three-year global strategy centered on positioning ANKTIVA as the core component of its Cancer BioShield platform. The strategy includes ongoing and planned clinical programs targeting multiple indications, including non-small cell lung cancer (NSCLC), glioblastoma and sepsis.
The company noted that intellectual property protections for ANKTIVA combination therapies extend beyond 2035, supporting long-term exclusivity alongside checkpoint inhibitor treatments.
Management Commentary
Dr. Patrick Soon-Shiong, Founder, Executive Chairman, and Global Chief Scientific and Medical Officer, highlighted the company’s accelerating international expansion and described the approval of ANKTIVA combined with checkpoint inhibitors for metastatic NSCLC as a major milestone. He emphasized continued engagement with global regulators, including the U.S. Food and Drug Administration, to pursue additional accelerated approval pathways.
Outlook
Looking ahead, ImmunityBio plans to expand global commercialization while advancing clinical trial enrollment across multiple indications. The company intends to submit additional data to the FDA related to ANKTIVA for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and pursue further label expansions across additional tumor types.
Management said its growing partnership network and newly established international subsidiaries are expected to support continued commercial momentum and long-term shareholder value creation.